4.6 Article

Characterization of Cell Free Plasma Methyl-DNA From Xenografted Tumors to Guide the Selection of Diagnostic Markers for Early-Stage Cancers

Journal

FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.615821

Keywords

whole-genome bisulfite sequencing; xenograft mice; early stage cancers; diagnosis; cell free methyl-DNA; colon cancer

Categories

Funding

  1. Ontario Institute for Cancer Research - Government of Ontario
  2. Manitoba Research Chair fund
  3. UMGF scholarship
  4. Research Manitoba Scholarship
  5. CancerCare Manitoba Foundation [761017325]
  6. Canadian Cancer Society Research Institute Grant [702459]
  7. NSERC Discovery Grant [RGPIN-2015-04144]
  8. Education Department of Guangxi, China

Ask authors/readers for more resources

The study utilized whole-genome bisulfite sequencing of circulating cell-free DNA from mice xenografted with human tumors and early stage cancer patients to identify potential cancer markers. Specific differentially methylated regions (DMRs) were found to be associated with tumourigenesis and could be used to distinguish different types of cancer and healthy controls, providing a threshold for precise diagnosis of early stage cancers.
Circulating cell-free methyl-DNA (mcfDNA) contains promising cancer markers but its low abundance and possibly diverse origin pose challenges toward the accurate diagnosis of early stage cancers. By whole-genome bisulfite sequencing (WGBS) of cell-free DNA (cfDNA) from about 0.5 mL plasma of mice xenografted with human tumors, we obtained and aligned the reads to the human genome, filtered out the mouse and carrier bacterial sequences, and confirmed the tumor origin of methyl-cfDNA (mctDNA) by methylation-sensitive restriction enzyme digestion prior to species-specific PCR. We estimated that human tumor-specific reads (ctDNA) or mctDNA comprised about 0.29 or 0.01%, respectively of the xenograft mouse cfDNA, and about 0.029 or 0.001% of the cfDNA of human early stage cancer patients. Similar WGBS of early stage (0-II, node- and metastasis-free) breast, lung or colorectal cancer samples identified hundreds of specific DMRs (differentially methylated regions) compared to healthy controls. Their association with tumourigenesis was supported by stage-dependent methylation, tumor suppressor or oncogene clusters, and genes also identified in the xenograft samples. Using 20 three-cancer-common and 17 colorectal cancer-specific DMRs in combination (top 0.0018% of the WGBS methylation clusters) was sufficient to distinguish the stage I colorectal cancers from breast and lung cancers and healthy controls. Our data thus confirmed the tumor origin of mctDNA by sequence specificity, and provide a selection threshold for authentic tumor mctDNA markers toward precise diagnosis of early stage cancers solely by top DMRs in combination.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available